BioSpace News Archive

DarioHealth Corp announced today two new studies published in the leading peer-reviewed journal for digital health and medicine, Journal of Internet Medicine (JMIR), including a Randomized Controlled Trial (RCT) demonstrating the impact of a digital stress reduction program for teens.

Parhelia Biosciences is excited to announce the launch of the Parhelia Spatial Station at the American Association for Cancer Research Conference.

Saluda Medical, Inc. announced that key US commercial payers, including Cigna and EviCore, have updated their policies to include coverage for the use of the Evoke® closed-loop spinal cord stimulation System.

Lexogen, a biotech company dedicated to advancing RNA research with innovative RNA-Seq products, is pleased to introduce solutions specifically optimized for transcriptomics from challenging FFPE samples.

Anatomage Inc., a leader in medical visualization technology, announced technological enhancements to Anatomage Lessons.

NorthStar Medical Radioisotopes, LLC, a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, today announced the signing of a Clinical Supply Agreement with Clarity Pharmaceuticals for the production of 67Cu-SAR-bisPSMA drug product for Clarity’s Phase I/II and Phase III trials.

Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced advancements in both clinical programs and one preclinical program.

The NIMML Institute announced that it will present four abstracts regarding novel mechanistic insights related to the pharmacological activation of LANCL receptors at Immunology2024, the 107th Annual Meeting of the American Association of Immunologists.

Cybin Inc. is pleased to announce that Doug Drysdale, Cybin’s Chief Executive Officer, will present at the 2024 Bloom Burton & Co. Healthcare Investor Conference, taking place April 16-17, 2024 in Toronto, Ontario.

AIM ImmunoTech Inc. today announced top-line interim data indicating that combining Ampligen (rintatolimod) with Keytruda (pembrolizumab) in the treatment of recurrent ovarian cancer may have a powerful synergistic effect, leading the investigator to conclude that the combination therapy could be far more effective than pembrolizumab alone as a therapy for the disease.